Core Insights - Carlsmed, Inc. reported preliminary revenue of approximately $15.2 million for Q4 2025, reflecting a growth of about 61% compared to Q4 2024 [1][5] - For the full year 2025, the company achieved revenue of approximately $50.5 million, marking an increase of around 86% over 2024 [1][5] Company Performance - The fourth quarter performance highlights a transformational year for Carlsmed, driven by the aprevo® platform technology, which enhances procedural predictability and aims to improve clinical outcomes in spine fusion [2] - In 2025, Carlsmed added 101 new surgeon users, resulting in a 61% increase in the total surgeon user base compared to the previous year [2] - The company anticipates continued growth and recognition of the aprevo® technology in 2026, particularly following the launch of aprevo® cervical, which has received positive early feedback from surgeons [2] Company Overview - Carlsmed is focused on pioneering AI-enabled personalized spine surgery solutions, with a mission to enhance outcomes and reduce healthcare costs associated with spine surgery [3]

CARLSBAD, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced the publication of a new retrospective cohort study in Global Spine Journal demonstrating that 3D preoperative planning combined with patient-specific, anatomically designed interbody implants significantly reduces mechanical complication–related reoperations in complex adult spinal deformity (ASD) surgery. The study compared 2-year revision rates among ASD patients receiving Carl ...

CARLSBAD, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (“Carlsmed”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that in the Hospital Inpatient Prospective Payment Systems Final Rule (IPPS) for fiscal year (FY) 2026, the Centers for Medicare & Medicaid Services (CMS) granted New Technology Add-On Payment (NTAP) reimbursement to cervical fusion procedures using the company’s aprevo® personalized interbody implants. The NTAP program is d ...